Bai and colleagues conducted a retrospective analysis in which 28 patients had BRAF V600E-mutated metastatic acral melanoma and an ORR of 38.1% following treatment with BRAF-targeted therapy, suggesting a lower response rate than those reported with BRAF-mutant non-acral cutaneous melanoma [40]. Here, BRAF is linked to acral lentiginous melanoma.